Biologics company Theradaptive's lead therapeutic, OsteoAdapt SP, has been featured in a preclinical spinal fusion study published in Spine, a prominent, peer-reviewed publication for spinal surgeons.
Theradaptive currently targets protein therapeutics for spine, orthopedics, soft tissue repair and targeted immuno-oncology, according to a Nov. 6 press release.
Here are five things to know about the new efficacy study:
1. The study demonstrated the preclinical safety and efficacy of OsteoAdapt SP in a clinically relevant large animal model.
2. Results showed faster and more robust new bone formation within the interbody cage, performing as well as or better than the gold standard.
3. OsteoAdapt SP is an investigational therapeutic designed for patients with degenerative disc disease. Theradaptive's engineered protein is a modified, adhesive variant of the bone-forming growth factor bone morphogenetic protein-2.
4. The preclinical study compared OsteoAdapt SP with ICBG in a lumbar interbody fusion model. Sheep underwent lateral lumbar fusion surgery with either polyetheretherketone or titanium interbody cages packed with low or high doses of OsteoAdapt SP or ICBG. Outcomes were evaluated at 8-, 16- and 26-week intervals.
5. Key findings concluded that the use of AMP2, Theradaptive's proprietary adhesive variant of BMP-2, showed healing outcomes equivalent to or better than ICBG. The precise delivery of the protein assisted healing and reduced the risk of off-target effects.